When ATH:
N07bb

Pharmacological action

Antialcoholic, hepatoprotective and detoxification agent, pyridoxine derivative (Vitamin B6). Accelerating the elimination of ethanol and acetaldehyde the body, activates enzymes, involved in the metabolism of ethanol. Restores the ratio of saturated and unsaturated free fatty acids in plasma, warns the primary structural degeneration of hepatocytes; inhibits the formation of collagen and fibronectin, It prevents the development of fibrosis and cirrhosis. It reduces craving for ethanol, It reduces the severity of psychic and somatic symptoms of hangover, reduces the relief of alcohol withdrawal syndrome. It normalizes the function of the liver detoxication, improves the mental state of patients, causing regression of depressive symptoms. It creates conditions for obtaining favorable results during the installation to change the psycho-alcoholic stereotype.

Pharmacokinetics

Absorption vыsokaya, биодоступность – 60-80%, Plasma protein binding - 50%, T1/2 – 40-60 m. Метаболизируется в печени до активных метаболитов – пиридоксина и пирролидона карбоксилата. Report the news - 45-50% during 24 no; через ЖКТ – 35-50% during 96 no.

Testimony

Acute alcohol intoxication, alcohol withdrawal syndrome, astenodepressivnyh state of psychotic nature.

В составе комбинированной терапии – заболевания печени различной этиологии.

Dosage regimen

При острой алкогольной интоксикации – 600 mg / m or 600-900 mg / drip, during 1.5 no (breeding 500 ml 0.9% sodium or hloridal 5% dextrose), 1 time /

При алкогольном абстинентном синдроме – 900 mg / drip, 1 time /, during 3-7 days, depending on the severity of the patient.

When alcoholic hepatopathy, при проведении поддерживающей противорецидивной терапии хронического алкоголизма – в/м, by 500 mg, 3 Минимальная продолжительность лечения – 90 days.

Заболевания печени и астенодепрессивные состояния – внутрь по 500 mg 3, длительность приема – не менее 90

Side effect

Maybe: allergic reactions.

Contraindications

Pregnancy, lactation, Hypersensitivity to matedoksinu.

Cautions

C wary of patients, receiving antiparkinsonian drugs.

Drug Interactions

In an application reduces the effectiveness of levodopa.

Published by
Vladimir Andreevich Didenko

This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.

Read More